

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



NetDragon

NetDragon Websoft Holdings Limited

網龍網絡控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 777)

**(1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR
AND
(2) CHANGE IN COMPOSITION OF BOARD COMMITTEES**

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of NetDragon Websoft Holdings Limited (the “**Company**”) hereby announces that with effect from 29 August 2025, Dr. Lo Wing Yan, William (“**Dr. Lo**”) has been appointed as an independent non-executive Director, the chairman of the Remuneration Committee, a member of the Audit Committee and the Nomination Committee.

Biographical details of Dr. Lo

Dr. Lo Wing Yan, William, *JP*, aged 64, is an experienced executive in the TMT (technology, media and telecommunications), retail, finance and education sectors. He started his career in McKinsey & Company Inc. as a strategy consultant and held senior positions in China Unicom, Hong Kong Telecom IMS Limited, Citibank Hong Kong, I.T. Limited, South China Media Group and Kidsland International Holdings Limited in the past. Dr. Lo graduated from Cambridge University with a M. Phil. degree in Pharmacology and a Ph.D. degree in Molecular Neuroscience.

Dr. Lo is the chairman and founding governor of the Charles K. Kao Foundation for Alzheimer’s Disease, he is also the founding governor of the ISF Academy and the chairman of Junior Achievement Hong Kong. Dr. Lo has held numerous government appointments during his career including the Central Policy Unit, Broadcasting Authority, Stock Exchange’s Growth Enterprise Market (GEM) Listing Committee and the Hong Kong Applied Science and Technology Research Institute ASTRI. Dr. Lo is currently a member of the advisory committee of the School of Chinese Medicine at Hong Kong Baptist University, Institute of Web 3.0 Hong Kong, Hong Kong PropTech Association, Our Hong Kong Foundation and a board governor of the Hong Kong Adventist Hospital Foundation. In 1999, Dr. Lo was appointed a Justice of the Peace (JP) of the HKSAR Government for his contribution to Hong Kong.

Dr. Lo was an independent non-executive director of South Shore Holdings Limited (stock code: 577) from April 2020 to November 2022, Oshidori International Holdings Limited (stock code: 622) from June 2021 to June 2023, Jingrui Holdings Limited (stock code: 1862) from October 2013 to December 2024 and Nam Tai Property Inc. (NYSE: NTP) from July 2003 to November 2021. Currently, Dr. Lo is an independent non-executive director of Television Broadcasts Limited (stock code: 511), CSI Properties Limited (stock code: 497), OCI International Holdings Limited (stock code: 329) and CWT International Limited (stock code: 521). Dr. Lo is also an independent director of Regencell Bioscience Holdings Limited (NASDAQ: RGC). Save as otherwise disclosed herein, Dr. Lo has not held any directorships in other listed public companies.

Dr. Lo has entered into a letter of appointment with the Company commencing from 29 August 2025 for a term of three years, and is subject to retirement from office and re-election at the next following annual general meeting of the Company in accordance with the articles of association of the Company. Under the terms of his letter of appointment with the Company, Dr. Lo is entitled to have a Director's fee of HK\$54,000 per month. The Director's fee and any other components of the Director's remuneration package will be reviewed in each financial year of the Company.

Save as disclosed above, (i) Dr. Lo does not have, and is not deemed to have, any interests or short positions in any Shares, underlying Shares or debenture of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (ii) Dr. Lo does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company.

Save as disclosed above, to the best knowledge, information and belief of the Board, there are no other matters relating to the appointment of Dr. Lo which need to be brought to the attention of the shareholders of the Company and there is no other information concerning Dr. Lo that is required to be disclosed pursuant to Rule 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”).

Dr. Lo has confirmed that (a) he has satisfied all the criteria for independence as set out in Rule 3.13(1) to (8) of the Listing Rules; (b) he has no past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (c) there are no other factors that may affect his independence at the time of his appointment.

The Board would like to extend its warm welcome to Dr. Lo on his appointment.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

Following the appointment of Dr. Lo as an independent non-executive Director of the Company, the chairman of the Remuneration Committee, a member of the Audit Committee and the Nomination Committee with effect from 29 August 2025, the Company has complied with the relevant requirements of Rules 3.10(1), 3.10A, 3.11, 3.21 and 3.23 of the Listing Rules.

The board of the Company hereby announce that Ms. Lin Yun (“**Ms. Lin**”), an executive Director of the Company, has been appointed as a member of the Nomination Committee with effect from 29 August 2025.

The Board would like to express its warmest welcome to Ms. Lin for joining the Nomination Committee.

By order of the Board
NetDragon Websoft Holdings Limited
Liu Dejian
Chairman

Hong Kong, 29 August 2025

As at the date of this announcement, the Board comprises five executive Directors, namely Dr. Liu Dejian, Dr. Leung Lim Kin Simon, Mr. Liu Luyuan, Mr. Chen Hongzhan and Ms. Lin Yun; one non-executive Director, namely Mr. Lin Dongliang; and three independent non-executive Directors, namely Mr. Li Sing Chung, Matthias, Mr. Liu Sai Keung, Thomas and Dr. Lo Wing Yan, William.